Meso Scale Diagnostics LLC

Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, manufactures electrochemiluminescence-based immunoassay instruments, multiplex assay kits, and related laboratory diagnostic equipment and supplies to federal agencies as a prime contractor on nearly all awards (99% of recent awards). The company is a Native American-owned small business headquartered in Rockville, Maryland, structured as a for-profit limited liability company. The vendor competes exclusively on full-and-open, unrestricted basis — no set-aside designations recur across the prime footprint.

Meso Scale Discovery's core capability portfolio centers on electrochemiluminescence detection platforms for biomarker and immunological testing. Representative work includes manufacturing biodefense assay kits and performance qualification kits for the Joint Program Executive Office for Chemical and Biological Defense (delivery orders ranging from $63,928 to $409,369); supplying MESO QuickPlex SQ 120MM readers and related plate reader systems to the National Institutes of Health, CDC Pittsburgh, FDA, and VA (equipment purchases in the $59,000–$230,840 range); and delivering multiplex serology assays, V-PLEX neuroinflammation panels, and custom cytokine analysis plates to NIAID, NIH Clinical Center, and various NIH institutes for COVID-19 vaccine development, influenza vaccine studies, and neurodegenerative disease research. The vendor also holds a $23.2 million definitive contract with HHS Office of the Assistant Secretary for Preparedness and Response for assays supporting COVID-19 vaccine development efforts.

Customer concentration is extreme and dollar-weighted toward defense biodefense programs. The top five funding agencies by potential value account for approximately 99% of the combined portfolio value: the Department of the Army Joint PEO Chemical and Biological Defense anchors the distribution with $8.33 billion in combined potential value across 29 awards — a portfolio-skewing figure reflecting the vendor's position on massive indefinite delivery contracts and delivery orders for biodefense assay manufacturing. By award count, however, NIAID leads with 171 awards valued at $21.6 million combined potential value, followed by Army Medical Command (68 awards, $14 million), CDC Pittsburgh (48 awards, $3.7 million), Army Materiel Command Research Development and Engineering (44 awards, $9.6 million), and FDA (43 awards, $1.3 million). The vendor has served 75 distinct agencies. The divergence between count and value rankings reflects two customer profiles: NIAID places frequent small purchase orders ($10,000–$150,000) for assay kits and service agreements; Army biodefense programs issue fewer, much larger task orders under standing IDCs.

The vendor holds multiple indefinite delivery contracts anchoring recurring task order activity. The largest parent vehicle is an $8.7 million IDC with the Joint Program Executive Office for Chemical and Biological Defense, which funds biodefense assay kit manufacturing. A $25 million single-award IDC with Defense Logistics Agency Medical Supply Chain (awarded June 2024, expires June 2029) has already generated 11 task orders ranging from $2,200 to $103,173 for multiplex serology assays, plate reader systems, and consumables. Defense Health Agency holds a $2.28 million single-award IDC (expires August 2029) for reagents, consumables, assays, and equipment. Army Acquisition Support Center holds multiple IDCs with ceilings up to $3.5 million. These vehicles position Meso Scale Discovery as a standing supplier of specialized assay technology across defense health and biodefense missions.

Activity has declined year over year: 57 awards in 2022, 70 in 2023, 43 in 2024, 23 in 2025, and 10 through mid-2026. The source covers 919 total awards (prime and sub, all federal sources) with combined potential value of $8.52 billion against $208 million obligated (2% of ceiling value, typical for IDCs with large multi-year ceilings). Seventeen awards face ultimate completion within the next twenty-four months, representing $24.4 million in recompete exposure concentrated in the NIAID and Army biodefense customer bases.

Meso Scale Discovery operates as a pure prime contractor (99% of awards); subcontracting is negligible. Service Contract Inventory data shows only $36 thousand in SCI-reportable invoiced revenue across FY2022–FY2024 at a median government-paid rate of $217.66/hr, reflecting the vendor's goods-dominant business model — most federal activity involves procurement of physical equipment and consumables rather than labor-hour services above the SCI threshold. The SCI footprint does not represent total federal revenue and is substantially smaller than the vendor's overall invoice stream.

Federal grant work complements the contract portfolio. Meso Scale Discovery serves as prime recipient of a $997,807 Defense Health Agency Project Grant (CFDA 12.420, Military Medical Research and Development) for ultrasensitive immunoassays targeting TDP-43 pathology in amyotrophic lateral sclerosis, extending through June 2028. The vendor received a $704,431 DHA grant for ALS clinical trial immunoassay development (September 2023–August 2025), a $2+ million NIAID Cooperative Agreement for next-generation influenza vaccine assay development (May 2023–April 2025), and a $1.1 million National Institute of Diabetes and Digestive and Kidney Diseases grant for pancreatic extracellular vesicle biomarker detection (September 2022–May 2027). The vendor also subcontracts to University of California Irvine and Arizona State University on NIH-funded tuberculosis diagnostics and cancer biomarker validation grants, performing electrochemiluminescence-based assay optimization and biomarker testing.